Latigo Biotherapeutics
CA - Thousand OaksBiotechnology
Focus: Latigo Biotherapeutics is a Series B-stage biotech focused on non-opioid pain relief, headquartered in Thousand Oaks, California. The company is pursuing novel approaches to acute and chronic pain management with a pipeline of investigational compounds.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
5
Should You Work at Latigo Biotherapeutics?
AI assessmentLatigo is a high-risk, high-reward Series B play best suited for candidates seeking equity upside, clinical-stage focus, and involvement in a pain-relief pipeline with recent IPO momentum.
Why Work Here
- IPO filing announced (July 2026) signals potential near-term liquidity event and equity upside for early employees
- Focused therapeutic area (non-opioid pain) addresses major unmet medical need with tailwinds from post-Vertex market momentum
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Help build intelligence for Latigo Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.